ci 994 has been researched along with Inflammation in 1 studies
tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Marquardt, V | 1 |
Theruvath, J | 1 |
Pauck, D | 1 |
Picard, D | 1 |
Qin, N | 1 |
Blümel, L | 1 |
Maue, M | 1 |
Bartl, J | 1 |
Ahmadov, U | 1 |
Langini, M | 1 |
Meyer, FD | 1 |
Cole, A | 1 |
Cruz-Cruz, J | 1 |
Graef, CM | 1 |
Wölfl, M | 1 |
Milde, T | 1 |
Witt, O | 1 |
Erdreich-Epstein, A | 1 |
Leprivier, G | 1 |
Kahlert, U | 1 |
Stefanski, A | 1 |
Stühler, K | 1 |
Keir, ST | 1 |
Bigner, DD | 1 |
Hauer, J | 1 |
Beez, T | 1 |
Knobbe-Thomsen, CB | 1 |
Fischer, U | 1 |
Felsberg, J | 1 |
Hansen, FK | 1 |
Vibhakar, R | 1 |
Venkatraman, S | 1 |
Cheshier, SH | 1 |
Reifenberger, G | 1 |
Borkhardt, A | 1 |
Kurz, T | 1 |
Remke, M | 1 |
Mitra, S | 1 |
1 other study available for ci 994 and Inflammation
Article | Year |
---|---|
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammat
Topics: Animals; Cerebellar Neoplasms; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Inflammation; M | 2023 |